Browsing Tag
single-domain antibodies
1 post
Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?
Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions.